24/7 Market News Snapshot 10 March, 2025 – Mineralys Therapeutics, Inc. Common Stock (NASDAQ:MLYS)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:MLYS) are discussed in this article.
Mineralys Therapeutics, Inc. (MLYS) is witnessing a significant surge in investor interest, with its shares reaching $15.57—a nearly 48% increase from the previous close of $10.52 during pre-market trading. This remarkable price movement aligns with the company’s announcement of encouraging topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 clinical trials, which evaluate lorundrostat, a new treatment for uncontrolled and resistant hypertension.

The Launch-HTN trial demonstrated a compelling 16.9 mmHg reduction in systolic blood pressure after six weeks of treatment with lorundrostat 50 mg, showing a sustained decrease of 19.0 mmHg by week 12. The clinical significance is further highlighted by the placebo-adjusted reductions of 9.1 mmHg and 11.7 mmHg at weeks 6 and 12, respectively. In parallel, the Advance-HTN trial indicated a noteworthy 7.9 mmHg placebo-adjusted reduction in systolic blood pressure using 24-hour ambulatory monitoring, underscoring lorundrostat’s potential effectiveness in treating approximately 15 to 20 million individuals facing uncontrolled hypertension.

Jon Congleton, CEO of Mineralys Therapeutics, expressed excitement over these results, emphasizing lorundrostat’s prospects for regulatory approval and the potential transformational impact on patient care. The trials also indicated a favorable safety and tolerability profile, further enhancing confidence in the treatment’s benefit-risk ratio.

The complete trial findings are slated for presentation on March 29, 2025, at the American College of Cardiology Scientific Sessions, with additional data expected to be shared in peer-reviewed journals and at medical conferences. As Mineralys continues its commitment to tackling hypertension and related health concerns, the advancement of lorundrostat marks a significant milestone in addressing this prevalent public health issue.

Related news for (MLYS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.